Status
Conditions
Treatments
Study type
Funder types
Identifiers
About
Although several studies have revealed signaling pathways as well as genes potentially involved in the development of esophageal atresia (EA), our understanding of the pathophysiology of EA lags behind improvements in the surgical and clinical care of patients born with this anomaly. However, a causative genetic abnormality can be identified in less than 10% of patients, even using more recent next-generation sequencing techniques. As most cases of EA associated with tracheoesophageal fistula (TOF) are sporadic, and the familial recurrence rate is low (1%), this suggests that epigenetic and environmental factors also contribute to the disease. Further investigations are needed to better understand the mechanisms underlying EA. That information can come from the oesophageal biopsies that are collected in routine care and long-term storage at the hospital. However, the impact of the length of the storage is still unknown.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Born with esophageal atresia Anastomosis performed in Lille hospital Parents consent
- Control group : Born with esophageal atresia
Exclusion criteria
Parents refusing to participate in the study
Primary purpose
Allocation
Interventional model
Masking
6 participants in 2 patient groups
Loading...
Central trial contact
Mélanie Leroy, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal